Cinclus Pharma Confirms Seven-Member Board and Appoints New Director at Extraordinary Meeting

Cinclus Pharma Holding AB ( (SE:CINPHA) ) has issued an update.

Cinclus Pharma Holding AB held an Extraordinary General Meeting on 19 January 2026, where shareholders approved the Nomination Committee’s proposal to maintain a seven-member Board of Directors and keep the existing remuneration structure in place until the next Annual General Meeting. The meeting also elected Kjell Andersson as a new board member for the same term, following the resignation of board member Peter Unge, signaling a controlled but notable change in the company’s governance as it advances its late-stage development program for GERD treatments.

The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.

More about Cinclus Pharma Holding AB

Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Its lead product candidate, linaprazan glurate—a prodrug of the P-CAB linaprazan originally developed by AstraZeneca—targets gastroesophageal reflux disease (GERD) with the goal of providing more effective mucosal healing and symptom relief than current proton pump inhibitor therapies. The compound’s safety and efficacy have been supported by extensive Phase I and II data involving more than 3,000 participants, and the first Phase III study began in 2025 to address the significant unmet need among an estimated 10 million patients with severe GERD in the US and EU.

Average Trading Volume: 45,667

Technical Sentiment Signal: Buy

Current Market Cap: SEK888.9M

For an in-depth examination of CINPHA stock, go to TipRanks’ Overview page.